SCHEMBL2448418

SCHEMBL2448418

Cc1oc2ccccc2c1C=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.51
THRB P10828 1/20 0.51
MAPT P10636 3/20 0.47
TOP2A P11388 1/20 0.46
CA2 P00918 1/20 0.45
CYP2C19 P33261 6/20 0.44
EYA3 Q99504 2/20 0.44
MAOA P21397 2/20 0.43
ALDH1A1 P00352 1/20 0.43
GLA P06280 1/20 0.43
CYP3A4 P08684 1/20 0.43
HPGD P15428 1/20 0.43
PGAM1 P18669 1/20 0.43
CASP1 P29466 1/20 0.43
CASP7 P55210 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HSD17B10 Q99714 1/20 0.43
POLB P06746 1/20 0.43
ALDH2 P05091 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14261907 0.87 KDM4E (0.65) KDM4ETHRBMAPTTOP2ACA2
SCHEMBL18685767 0.80 KDM4E (0.47) KDM4ETHRBMAPTCA2CYP2C19
SCHEMBL21615029 0.80 KDM4E (0.47) KDM4ETHRBMAPTCA2CYP2C19
SCHEMBL15534884 0.80 KDM4E (0.47) KDM4ETHRBMAPTCA2CYP2C19
SCHEMBL24086761 0.78 KDM4E (0.46) KDM4EMAPTCA2CYP2C19EYA3
SCHEMBL5226658 0.78 KDM4E (0.53) KDM4ETHRBMAPTTOP2AMAOA
SCHEMBL9669090 0.77 KDM4E (0.55) KDM4ETHRBMAPTCA2CYP2C19
SCHEMBL19658527 0.77 KDM4E (0.55) KDM4EMAPTCA2CYP2C19EYA3
SCHEMBL15842324 0.76 KDM4E (0.56) KDM4ETHRBMAPTTOP2ACYP2C19
SCHEMBL715966 0.76 KDM4E (0.51) KDM4ETHRBMAPTTOP2AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12545672-B2 Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof DEBIOPHARM INTERNATIONAL S.A. (CH) 2026-02-10 US disclosed
US-12473283-B2 Compounds and their use DEBIOPHARM INTERNATIONAL S.A. (CH) 2025-11-18 US disclosed
EP-3880675-B1 ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF DEBIOPHARM INT SA (CH) 2024-11-06 EP disclosed
US-20240317740-A1 NOVEL COMPOUNDS AND THEIR USE DEBIOPHARM INTERNATIONAL S.A. (CH) 2024-09-26 US disclosed
CN-113272302-B Antibiotic compound, method for producing same, pharmaceutical composition containing same, and use thereof 德彪药业国际股份公司 2024-08-13 CN disclosed
CN-115151541-B Novel compounds and uses thereof 德彪药业国际股份公司 2024-06-25 CN disclosed
EP-4359079-A1 NOVEL COMPOUNDS AND THEIR USE Debiopharm International S.A. (CH) 2024-05-01 EP disclosed
CN-117881679-A Novel compounds and uses thereof 德彪药业国际股份公司 2024-04-12 CN disclosed
US-20230159519-A1 NOVEL COMPOUNDS AND THEIR USE DEBIOPHARM INTERNATIONAL S.A. (CH) 2023-05-25 US disclosed
US-20230159519-A1 NOVEL COMPOUNDS AND THEIR USE DEBIOPHARM INTERNATIONAL S.A. (CH) 2023-05-25 US disclosed
US-20070191459-A1 Use of Benzo-Heteroaryl Sulfamide Derivatives for Lowering Lipids and Lowering Blood Glucose Levels JANSSEN PHARMACEUTICA, N.V. (BE) 2007-08-16 US disclosed
US-20070191453-A1 USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF SUBSTANCE ABUSE AND ADDICTION SMITH-SWINTOSKY VIRGINIA L 2007-08-16 US disclosed
US-20070191451-A1 USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES AS NEUROPROTECTIVE AGENTS SMITH-SWINTOSKY VIRGINIA L 2007-08-16 US disclosed
US-20070191452-A1 USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN SMITH-SWINTOSKY VIRGINIA L 2007-08-16 US disclosed
EP-1794143-A1 NOVEL BENZO-FUSED HETEROARYL SULFAMIDE DERIVATIVES USEFUL AS ANTICONVULSANT AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 2007-06-13 EP disclosed
US-20060276528-A1 Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents ABDEL-MAGID AHMED F 2006-12-07 US disclosed
US-20060270856-A1 Process for preparation of sulfamide derivatives JANSSEN PHARMACEUTICA NV (BE) 2006-11-30 US disclosed
WO-2006127184-A1 PROCESS FOR PREPARATION OF SULFAMIDE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-30 WO disclosed
WO-2006023861-A1 NOVEL BENZO-FUSED HETEROARYL SULFAMIDE DERIVATIVES USEFUL AS ANTICONVULSANT AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 2006-03-02 WO disclosed
US-20060047001-A1 Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents JANSSEN PHARMACAEUTICA N.V. (BE) 2006-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159519-A1 NOVEL COMPOUNDS AND THEIR USE LSS, PGLS, LDHB KDM4E 175/4885THRB 2077/4885MAPT 1933/4885
US-20060276528-A1 Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents GABRA5, SULT2A1, SYNGR2 KDM4E 1073/4885THRB 3953/4885MAPT 701/4885
US-20070191451-A1 USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES AS NEUROPROTECTIVE AGENTS NLN, CTSA, SMN1; SMN2 KDM4E 3579/4885THRB 3293/4885MAPT 464/4885
US-20060047001-A1 Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents GABRE, GABRB2, GABRA2 KDM4E 1493/4885THRB 3723/4885MAPT 1366/4885
US-20240317740-A1 NOVEL COMPOUNDS AND THEIR USE PGLS, LSS, LAS1L KDM4E 95/4885THRB 3216/4885MAPT 1616/4885
US-20070191459-A1 Use of Benzo-Heteroaryl Sulfamide Derivatives for Lowering Lipids and Lowering Blood Glucose Levels LIPC, GPR119, APOB KDM4E 1961/4885THRB 1543/4885MAPT 4122/4885
US-12545672-B2 Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof MRPL21, EMG1, RRS1 KDM4E 1019/4885THRB 2131/4885MAPT 4422/4885
US-20070191452-A1 USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN OPRL1, SULT2A1, OPRK1 KDM4E 3537/4885THRB 2785/4885MAPT 3691/4885
US-12473283-B2 Compounds and their use LSS, PGLS, LDHB KDM4E 111/4885THRB 2353/4885MAPT 1798/4885
US-20060270856-A1 Process for preparation of sulfamide derivatives STS, SULT2A1, SULT1A1 KDM4E 2544/4885THRB 2815/4885MAPT 4094/4885
US-20070191453-A1 USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF SUBSTANCE ABUSE AND ADDICTION SULT2A1, SULT1A1, STS KDM4E 1979/4885THRB 1008/4885MAPT 3598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.